PharmaShots | Incisive News in 3 Shots

Subscribe Now

Immhance

Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III IMMhance Study for Moderate to Severe Plaque Psoriasis #WCD2019

Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III IMMhance Study for Moderate to Severe Plaque Psoriasis #WCD2019

June 11, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us